ECOG E2805
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma

ECOG E3805
CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer

ECOG E3803
(Hormone refractory prostate who received 2 Chemo's)
BMS-247550 Day 1, 8 & 15 in a 28 d cycle

CINJOG 080803 (NJ 1808)
-Hormone-Dependent PSA Progression after Local Therapy for Prostate Cancer (Stage D0)
Hydroxychloroquine 400mg per day

ECOG E5805
(Metastatic Hormone Refractory Prostate Cancer)
Reactivation of No Prior Chemotherapy Stratum 9/25/08 Halichondrin B Analog